Avadel Pharmaceuticals plc
Avadel Pharmaceuticals plc Fundamental Analysis
Avadel Pharmaceuticals plc (AVDL) shows moderate financial fundamentals with a PE ratio of -7558.74, profit margin of -0.11%, and ROE of -0.33%. The company generates $0.3B in annual revenue with moderate year-over-year growth of 5.05%.
Key Strengths
Areas of Concern
The stock receives a Fundamental Health Score of 31.4/100 based on profitability, valuation, growth, and balance sheet metrics. The F grade reflects weak fundamentals and significant financial concerns.
Fundamental Health Score
We analyze AVDL's fundamental strength across five key dimensions:
Efficiency Score
WeakAVDL struggles to generate sufficient returns from assets.
Valuation Score
ExcellentAVDL trades at attractive valuation levels.
Growth Score
ExcellentAVDL delivers strong and consistent growth momentum.
Financial Health Score
ExcellentAVDL maintains a strong and stable balance sheet.
Profitability Score
WeakAVDL struggles to sustain strong margins.
Key Financial Metrics
Is AVDL Expensive or Cheap?
P/E Ratio
AVDL trades at -7558.74 times earnings. This suggests potential undervaluation.
PEG Ratio
When adjusting for growth, AVDL's PEG of -75.09 indicates potential undervaluation.
Price to Book
The market values Avadel Pharmaceuticals plc at 21.39 times its book value. This suggests the stock is fully valued or overvalued on an asset basis.
EV/EBITDA
Enterprise value stands at 213.86 times EBITDA. This signals the market has high growth expectations.
How Well Does AVDL Make Money?
Net Profit Margin
For every $100 in sales, Avadel Pharmaceuticals plc keeps $-0.11 as profit after all expenses.
Operating Margin
Core operations generate 1.82 in profit for every $100 in revenue, before interest and taxes.
ROE
Management delivers $-0.33 in profit for every $100 of shareholder equity.
ROA
Avadel Pharmaceuticals plc generates $-0.14 in profit for every $100 in assets, demonstrating efficient asset deployment.
Following the Money - Real Cash Generation
Operating Cash Flow
Avadel Pharmaceuticals plc produces operating cash flow of $35.98M, showing steady but balanced cash generation.
Free Cash Flow
Avadel Pharmaceuticals plc generates strong free cash flow of $35.79M, providing ample flexibility for dividends, buybacks, or growth.
FCF Per Share
Each share generates $0.36 in free cash annually.
FCF Yield
AVDL converts 1.67% of its market value into free cash.
Financial Ratios Analysis
Valuation Ratios
P/E Ratio
Price to earnings ratio
-7558.74
vs 25 benchmark
PEG Ratio
Price/earnings to growth ratio
-75.09
vs 25 benchmark
P/B Ratio
Price to book value ratio
21.39
vs 25 benchmark
P/S Ratio
Price to sales ratio
8.55
vs 25 benchmark
Financial Health
Debt/Equity
Total debt to shareholders' equity
0.38
vs 25 benchmark
Current Ratio
Current assets to current liabilities
2.76
vs 25 benchmark
Efficiency Ratios
ROE
Return on equity percentage
-0.00
vs 25 benchmark
ROA
Return on assets percentage
-0.00
vs 25 benchmark
ROCE
Return on capital employed
0.03
vs 25 benchmark
How AVDL Stacks Against Its Sector Peers
| Metric | AVDL Value | Sector Average | Performance |
|---|---|---|---|
| P/E Ratio | -7558.74 | 29.43 | Better (Cheaper) |
| ROE | -0.33% | 800.00% | Weak |
| Net Margin | -0.11% | -20145.00% (disorted) | Weak |
| Debt/Equity | 0.38 | 0.30 | Weak (High Leverage) |
| Current Ratio | 2.76 | 4.64 | Strong Liquidity |
| ROA | -0.14% | -17936.00% (disorted) | Weak |
AVDL outperforms its industry in 2 out of 6 key metrics, but lagging in ROE.
Historical Growth Performance
5-Year Growth Trajectory
This section reviews Avadel Pharmaceuticals plc's 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.
Revenue CAGR
12.28%
Industry Style: Defensive, Growth, Innovation
High GrowthEPS CAGR
42.22%
Industry Style: Defensive, Growth, Innovation
High GrowthFCF CAGR
51.88%
Industry Style: Defensive, Growth, Innovation
High Growth